The use of mixtures of well-defined monoclonal antibodies may represent a step forward in the standardization of immunochemical assays. We developed and optimized working conditions for using such a mixture to determine apolipoprotein A-I in human sera by two independent techniques (electroimmuno-and immunonephelometric-assays). Six monoclonal antibodies, each addressed to distinct epitopes located at the surface of apolipoprotein A-I, were used in combination to permit a reproducible measurement of the protein, without prior delipidation of samples. Parallel standard curves for a high-density lipoprotein subfraction (HDL3, the primary standard) and a reference serum (the secondary standard) were obtained. Within-and between-run coeff icients of variation were acceptable for both methods. Apolipoprotein A-I concentrations, as measured in 60 subjects selected to present a large range of apolipoprotein content by electroimmunoassay (Yi) and immunonephelometnc assay (Y2) with monoclonal antibodies, compared well with those measured by the same techniques but with polyclonal antibodies Apolipoprotein A-I (Ape A-I), the major apolipoprotein of normal human plasma, is found in the high-density lipoprothins (HDL), and accounts for at least 55% of the protein in this fraction.2 Although the accurate determination of concentrations of Ape A-I in serum appears crucial to the assessment of risk of coronary artery disease (1), immunoassays for Ape A-I have not yet been satisfactorily standardized (2). The major problem derives from the fact that HDL is not a homogeneous molecular species (3) and that Ape A-I does not always express all its potential antigemc sites (4, 5), such that some sites are apparently masked by lipids in the intact hipoprotein. Consequently, variability in the exposure of these antigenic determinants on the lipoprotein surface results in apparent differences in detected Ape A-I protein mass, even within the same population (6, 7). The question therefore arises as to whether it is more suitable to determine Ape A-I epitopes easily accessible to antibodies and located on the surface on HDL, or to measure total Ape A-I in serum. The specificity of the antibodies used for the assays is therefore very important.
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The confounding effects of various and uncharacterized antibodies from pelyclonal antisera make the immunological methods greatly were immunized against HDL3 except those retained for the fusion secreting 2G11, for which the immunogen was purified Ape A-I. The production of hybrid cells and the use of an enzyme-linked immunosorbent assay to screen for antibody production have been described previously (16, 17 by the same procedure used in polyclonal EIA (23) . We punched 16 wells in the gel and dried the plates before storing them at 4#{176}C. Just before use, the plates were rehydrated for 30 mm with distilled water followed by Apoffim buffer (Labs. Sebia) for another 30 mm. After removing excess buffer, we applied to each well 3 pL of sample or standard appropriately diluted with water containing NaCl, 0.1 moJJL (saline), then applied 150 V for 4 h at room temperature for electrophoresis in pH 9.2 Apefllm buffer. Included in each run were three dilutions of the standard and one dilution of a quality-control serum, to assess calibration and reproducibility.
After electrophoresis, the plates were soaked vertically for 3 and 1 h at room temperature in saline and distilled water, respectively, then dried. hnmunoprecipitates corresponding to Ape A-I were stained with Coomassie Brilliant Blue R for 5 mm, then destained.
We measured peak height the center of the antigen well to the apex of the "rocket."
INA. For INA we used a Behring nephelometer (Behringwerke, Marburg, , and A16, the mixture of the six Mabs, and the Pabs with each of the different competitors had slopes that were not significantly different from one another, confirming that these antibodies recognize Ape A-I epitopes that were relatively easily accessible on all the Ape A-I-containing particles we tested. HDL2 and HDL3 varied in their expression of epitopes specifically detected by 2G1 1 and A30. Both of these antibodies may be specific for epitopes that participate in protein/lipid or protein/protein interactions, because HDL2 and HDL3 differ in their lipid and protein composition (24) .
Results

Characterization of the Mabs and Comparison with the Pabs
Assessment of the EIA and INA Procedures
Standardization. Figure 1 illustrates typical standard curves obtained in EIA and INA with HDL3 and the reference standard, and shows a very good parallelism between the different antigens. Figure 2 Precision. Repeated measurements (n = 33) of a single pool of normal human sera gave an average within-run assay CV of 2.8% and 1.6% in the EIA and INA, respectively. The between-run assay CV, assessed by performing 40 measurements on three specimens with low, normal, and high values of Ape A-I on four consecutive days, was respectively 7.9%, 7%, 5.3%, and 2.9%, 4.3%, and 5% for EIA and NA.
Accuracy.
The accuracy of the procedures was verified by adding to a diluted serum of known Ape A-I content various amounts of HDL. The mean percentage of added lipeprotein accounted for by EIA and INA was 103% and 95%, respectively.
Comparison with Pabs. We compared the results obtained by the two proposed methods by using the same mixture of Mabs with those obtained by similar procedures but with Pabs antisera; we used the same reference sera standard in all the assays. The results for 60 samples, selected to include a wide range of Ape A-I concentrations, are shown in Figure  3 . A very good correlation was obtained in both cases, and the means in each system were not significantly different.
Apo A-I assessment with Mabs. The results for Ape A-I concentrations in 60 samples, as measured by EIA (x) and INA (y) involving Mabs, were very well correlated (r = 0.96; y = 1.OSx + 0.13 g/L). To assess whether any changes in the immunoreactivity of Ape A-I-containing particles would be caused by removal of lipids, we compared the slopes of the calibration curves from five hyperlipemic sera before and after delipidation. There was no significant difference in the slopes of the calibration curves.
Discussion
Measurements of Ape A-I are complicated by the fact that in serum it is part of a large, biochemically heterogeneous particle, within which some of the antigenic sites are concealed (4, 5) . Consequently, results are strongly influenced by variations in the specificity of antisera, the standardization procedure, and the methodology used in a particular assay system (2) . Because Mabs are now available in large quantities and easily purified, and because they present a highly reproducible specificity, they constitute an attractive alternative to Pabs for apelipeprotein measurement (25) (26) (27) .
Among the numerous methods described for quantifying apolipoproteins, those based on precipitation in gel or liquid are the most commonly used. if Mabs are used in this way, one must mix several together to make them capable of precipitating all the relevant apolipoproteins. Such immunoassays for apolipoproteins B or A-I have already been described for radial immunodiffusion 25,26) . Recently, we have developed an ELA for Ape B quantification involving ready-to-use plates (Labs. Sebia) (27) . However, the use of a mixture of Mabs has not yet been examined for immunonephelometric determination of apolipoproteins.
We have described here the quantification of Ape A-I in human sera by using EIA and NA and a mixture of six different Mabs. Because such Ape A-I immunoassays are affected by in vitro modification of Ape A-I during storage (28), we have controlled the reactivity of the epitopes corresponding to the six Mabs and have ascertained the stability of this mixture for over three days at 4#{176}C and one month at -30#{176}C.
Of the six Mabs we used, four of them (4A12, 4B11, A03, A16) recognize the different Ape A-I-containing particles (total HDL, HDL2, and HDL3) with the same apparent affinity; together they bind 98% of 'I-labeled HDL (results not shown). The two other Mabs (2G11, A30) exhibitvariable reactivity for RDL2 or HDL3 (Table 1) , and including them in the mixture does not really enhance the maximum binding of labeled HDL (Table 2 ). Nevertheless, their presence is important to give the best definition of the rockets in EIA and a good stability of the lattice in NA. Mab 2G11 or A30 displayed different apparent affinities for the epitopes they recognized in HDL2 or HI)L3, respectively, as compared with their affinities in whole sera ( Table 2) . These discrepancies may be attributable to preservation of the immunological properties in native lipoproteins in sera, unlike ultracentrifugally isolated HDL2 or HDL3. The EIA we developed for Ape A-I is simple and reproducible, but the speed and precision of NA recommend it over EIA as the method of choice for large-scale measurements.
However, the immunonephelometric procedures may be inconvenient, and nonspecific light-scattering may be encountered, particularly in hyperlipoproteinemic serum (2). Nevertheless, we obtained a very good correlation between the two assays with Mabs, and encountered no false estimations by NA for hyperlipemic sera (because the nephelometer we used measures the difference in light-scatter occurring between two times). The large difference in the mean values obtained for Ape A-I with Mabs (1.35 ± 0.71 vs 1.56 ± 0.78 g/L, respectively, by EIA and NA) probably results from differences in the basic principles of the assays and reflects the standardization problems involved in immuneassays of apelipeproteins.
Use of the same antibodies and the same standard is not enough to solve this problem, because the accessibility of epitopes depends on various aspects of the methodology involved: buffer, dilution, protocol, etc.
As is well known, plasma lipids may cause a conformational change and (or) mask the antigenic site(s) on apolipoproteins (4, 5); thus the quantification of Ape A-I in sera with or without pretreatment is a controversial issue. Several studies have demonstrated that the antigenic sites of Ape A-I are partly masked in the intact HDL particle (29) and suggest that the determination of Ape A-I in HDL will give different values from those obtained after disintegration of the lipoprotein. Although some antigenic sites on Ape A-I in HDL are doubtless more readily accessible than others to antibodies (30), the location of these sites is not established. Recent evidence apparently indicates at least three distinct antigenic determinants on Ape A-I (31). The epitopes recognized by each of the Mabs that we used are all situated on the surface of the HDL particle (as shown by complete competition obtained in each case with native HDL); contrary to the studies concluding that the COOH-terminal portion of the Ape A-I molecule is more expressed in HDL (30), only one epitope, specifically recognized by 4A12, is located in this region (16).
In conclusion, we have described two precise and reproducible immunological assays for the determination of Ape A-I in plasma in which combined Mabs are used. These antibodies are surface-epitope-specific, thus permitting measurement without chemical treatment. The use of such a standardized reagent and a common secondary standard provides a useful alternative for determining Ape A-I in sera.
